Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to evaluate the safety profile and tolerability of rituximab in combination with different chemotherapy regimens.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Rituximab

Criteria

Inclusion Criteria:

• New diagnosed Stage III/IV NHLs

• Grades 1, 2 follicular lymphoma need to be treated

• mCD20 positive

• Have an expected survival of 3 months or more

• ECOG 0-2 grade

• Normal renal function

• ALT less than double normal level

Exclusion Criteria:

• Presence of CNS lymphoma

• Severe infectious disease or organic disease

• Having another malignant tumor

• Pregnant or breast-feeding female

• Organic heart disease, heart failure, II or higher grade AV bundle block.

• Subject is allergic to Rituximab

• Known HIV infection or chronic HBV infection